1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 28,400 | 28,800 | 08:56 | |
| 28,400 | 28,800 | 08:40 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AMPHASTAR Aktie jetzt für 0€ handeln | |||||
| 22.11.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference | 521 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and... ► Artikel lesen | |
| 18.11.22 | Amphastar Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.11.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference | 348 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration... ► Artikel lesen | |
| 08.11.22 | Amphastar authorizes $50M buyback | 2 | Seeking Alpha | ||
| 07.11.22 | Amphastar Pharmaceuticals Non-GAAP EPS of $0.38 misses by $0.01, revenue of $120.13M misses by $6.27M | 2 | Seeking Alpha | ||
| 07.11.22 | Amphastar Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.11.22 | Amphastar Pharmaceuticals Q3 2022 Earnings Preview | 1 | Seeking Alpha | ||
| 28.10.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022 | 263 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30... ► Artikel lesen | |
| 16.08.22 | Amphastar wins FDA approval for Epinephrine pre-filled syringes | 2 | Seeking Alpha | ||
| 16.08.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes | 372 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / August 16, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application... ► Artikel lesen | |
| 09.08.22 | Amphastar Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.08.22 | Amphastar sheds 14% after announcing FDA rejection of generic drugs | 5 | Seeking Alpha | ||
| 08.08.22 | Amphastar Pharmaceuticals Non-GAAP EPS of $0.39 beats by $0.04, revenue of $123.47M beats by $5.59M | 1 | Seeking Alpha | ||
| 08.08.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022 | 338 | ACCESSWIRE | Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the... ► Artikel lesen | |
| 01.08.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022 | 301 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / August 1, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022... ► Artikel lesen | |
| 19.07.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Vasopressin | 932 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated... ► Artikel lesen | |
| 06.06.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference | 432 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communications... ► Artikel lesen | |
| 24.05.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Regadenoson | 390 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... ► Artikel lesen | |
| 09.05.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022 | 258 | ACCESSWIRE | Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company")... ► Artikel lesen | |
| 02.05.22 | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022 | 365 | ACCESSWIRE | RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVARTIS | 78,46 | -100,00 % | NOVARTIS zahlt mehr Dividende | Trotzdem die Schweizer im vierten Quartal 2022 weniger verdient und umgesetzt haben, sollen die Aktionäre für das vergangene Jahr dennoch in den Genuss einer höheren Dividende kommen. Statt 3,10 Franken... ► Artikel lesen | |
| NOVO NORDISK | 121,86 | +0,56 % | JPMORGAN stuft NOVO NORDISK auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Novo Nordisk nach Zahlen auf "Overweight" mit einem Kursziel von 1100 dänischen Kronen belassen. Der Ausblick des Insulinherstellers... ► Artikel lesen | |
| ABBVIE | 132,02 | -0,51 % | AbbVie's Rinvoq approved by MHRA for Crohn's disease | ||
| MERCK & CO | 94,60 | -0,21 % | wikifolio whispers a.m. Merck Co., Walt Disney, Nvidia ... | Merck Co. 0.57% rabe5976 (20201102): Rebalancing: kauf 3 Stück á € 98,10 (27.01. 08:46) >> mehr comments zu Merck Co.: www.boerse-social.com/launch/aktie/merck_co_dl-01 Walt Disney -0.19% GoldeselTrading... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 67,22 | +0,84 % | Exscientia plc: Exscientia kündigt erste Studie am Menschen für den von Bristol Myers Squibb lizenzierten PKC-Theta-Inhibitor EXS4318 an | - EXS4318 ist der erste von Exscientia entwickelte Kandidat im Bereich Immunologie und Entzündungen und sein viertes Molekül, das in die Klinik kommt -
Exscientia hat einen potenziell ersten potenten... ► Artikel lesen | |
| ABBOTT LABORATORIES | 102,48 | -0,35 % | Abbott: The Partnerships Changing How You Manage Diabetes | NORTHAMPTON, MA / ACCESSWIRE / February 1, 2023 / Abbott AbbottGo ahead, call it a comeback.There's new energy around connecting - whether among people or technologies - thanks to the not-so-distant... ► Artikel lesen | |
| ELI LILLY | 306,15 | +1,09 % | Kurs fällt um 4,74 Prozent: Aktie von Eli Lilly unter Druck | Keinen Grund zur Freude haben Aktionäre von Eli Lilly : Das Papier verliert deutlich an Wert. Zu den großen Verlierern des Tages am Aktienmarkt zählt derzeit die Eli Lilly-Aktie. Im Vergleich zum Schlusskurs... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 77,57 | +0,15 % | Edwards Lifesciences Corp. Q4 Profit Increases, beats estimates | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) revealed earnings for its fourth quarter that increased from the same period last year and beat the Street estimates.The company's bottom... ► Artikel lesen | |
| AMARIN | 1,750 | -1,69 % | Sarissa Capital Management LP: Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders | Vote the Blue Card "FOR" the appointment of the Sarissa Nominees to the Board Vote the Blue Card "FOR" the Removal of Chairman Per Wold-Olsen from the Board
Sarissa Capital Management LP ("Sarissa")... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 209,75 | -0,36 % | Alnylam Announces Preliminary Q4 Global Net Product Revenues | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced its preliminary fourth quarter 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.Preliminary... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,566 | +0,93 % | Achieve Life Sciences Announces Granting of New Hire Inducement Award | ||
| AXSOME THERAPEUTICS | 70,00 | +2,85 % | Axsome Therapeutics, Inc.: Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27 | ||
| ACADIA PHARMACEUTICALS | 17,112 | 0,00 % | Analyst Expectations for ACADIA Pharmaceuticals' Future | ||
| UCB | 72,90 | -0,52 % | UCB, Novo Nordisk, Gilead rank highest among pharmas for HCP customer experience - survey | ||
| SEELOS THERAPEUTICS | 0,779 | +7,47 % | Seelos: In Vivo Data Shows Potential Of SLS-004 As Disease-modifying Gene Therapy In Parkinson's | WASHINGTON (dpa-AFX) - Seelos Therapeutics, Inc. (SEEL) announced in vivo data showing that a single dose of SLS-004 downregulated the production of alpha-synuclein. This reduction of ?-synuclein... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
